Rashmin C. Savani Recognized for Career Achievements by Hellenic Society of Biochemistry and Molecular Biology

September 22, 2026

The Hellenic Society of Biochemistry and Molecular Biology presented two scientific achievement awards to Rashmin C. Savani, Head of Azome Therapeutics’ Scientific Advisory Board, last month in Eretria, Greece.

Currently Professor, Nemours Eminent Scholar and Chair of Pediatrics at the University of Florida College of Medicine, Dr. Savani was recognized during the 2026 FEBS Advanced Lecture Course, where he also presented a talk on RHAMM as a link between extracellular matrix remodeling and innate immune activation and Angiogenesis.

The awards include the Society’s Award of Scientific Excellence in recognition of Dr. Savani’s distinguished scientific career and outstanding contributions to the advancement of Biochemistry, Molecular Biology, and Extracellular Matrix Research. Additionally, the Society’s Hellenic Matrix Biology Section presented Dr. Savani with an award for his significant contribution and scientific achievements in the fields of extracellular matrices and translational medicine.

About Azome Therapeutics

Azome Therapeutics is focused on developing selective RHAMM (Receptor for Hyaluronan-Mediated Motility) antagonists of the NLRP3 inflammasome, an inflammatory pathway critical to the development of a wide variety of diseases, including pulmonary and neuroinflammatory diseases. The company’s lead candidate, AZM-152, is a RHAMM-derived antagonist that blocks key priming and activation signals involved in the aberrant activation of the NLRP3 inflammatory cascade. Last year, the company entered into a Cooperative Research and Development Agreement (CRADA) with the National Center for Advancing Translational Sciences (NCATS) to investigate AZM-152 in bronchopulmonary dysplasia (BPD).

Azome Therapeutics Presents at 7th Annual Inflammasome Therapeutics Summit

November 6, 2025

Azome Therapeutics CEO Elliott Gruskin and the Head of the company’s Scientific Advisory Board Rashmin Savani were among the expert speakers at the 7^th Annual Inflammasome Therapeutics Summit – the leading industry forum dedicated exclusively to inflammasome-targeted drug development – held November 4-6 in Boston, MA

As one of the summit’s keynote speakers, Dr. Savani discussed the development of the company’s novel RHAMM-targeted antagonist technology. His presentation demonstrated how the company’s peptides and small molecule inhibitors effectively block RHAMM-target interactions required for activation of the NLRP3 inflammasome to support precise immune modulation.

This year’s summit also featured Azome’s Gruskin in a fireside chat with CEOs on addressing stakeholder needs and positioning inflammasome therapies for clinical, commercial and capital success.

Azome’s novel RHAMM (Receptor for Hyaluronan-Mediated Motility) antagonist technology platform and its lead drug candidate, AZM-152, which blocks inflammasome activation, has demonstrated excellent potential for advancing the treatment of severe inflammatory diseases, including several with significant unmet needs.  Last November, the company announced that it had entered into a Cooperative Research and Development Agreement (CRADA) with the National Center for Advancing Translational Sciences (NCATS) to investigate AZM-152 in bronchopulmonary dysplasia (BPD).

About Azome Therapeutics

Azome Therapeutics is focused on developing selective RHAMM antagonists of the NLRP3 inflammasome, an inflammatory pathway critical to the development of a wide variety of diseases, including acute lung injury, acute respiratory distress syndrome, bronchopulmonary dysplasia, systemic sepsis, acute liver and kidney injury, and pneumonia.  The company’s lead candidate, AZM-152, is a RHAMM-derived antagonist that blocks key priming and activation signals involved in the aberrant activation of the NLRP3 inflammatory cascade.

Azome Therapeutics Featured at Hyaluronan 2025

October 9, 2025

Dr. Rashmin Savani, the Head of Azome Therapeutic’s Scientific Advisory Board, was a featured speaker at this summer’s 15th conference of the International Society for Hyaluronan Science (Hyaluronan 2025) held June 8-12 in St. Charles, IL.

Dr. Savani, a leading expert in the biology of preterm lung development, injury and repair, was invited to present on the latest scientific insights into the role of NLRP3 inflammasome activation and the development of bronchopulmonary dysplasia.  BPD, a chronic lung disease, is common among preterm infants where respiratory failure is treated with ventilator and oxygen therapy. 

During the conference, Azome Therapeutics also presented three scientific posters including one on hyaluronan as a predictive biomarker of death and BPD in preterm infants with respiratory failure.  Additional poster presentations focused on NLRP3 inflammasome activation in an animal model of sepsis and the integral role of RHAMM ((Receptor for Hyaluronan-Mediated Motility) in the activation of the NLRP3 inflammasome.

The company’s novel RHAMM antagonist technology platform and its lead drug candidate, AZM-152, which blocks inflammasome activation, has demonstrated excellent potential for advancing the treatment of severe inflammatory diseases, including several with significant unmet needs.  Last November, Azome announced that it had entered into a Cooperative Research and Development Agreement (CRADA) with the National Center for Advancing Translational Sciences (NCATS) to investigate AZM-152, the company’s novel inflammasome antagonist, in BPD.

“It was an honor to be invited to speak at Hyaluronan 2025 and have this prestigious opportunity to share the findings from our research with other society members,” said Dr. Savani. “Based on our early data, we are very hopeful that our novel, first-in-class therapy will one day help the thousands of families affected by BPD, one of the most common chronic lung diseases of childhood for which there are no current therapeutic options and no effective means of prevention.”

About Azome Therapeutics

Azome Therapeutics is focused on developing selective antagonists of the NLRP3 inflammasome, an inflammatory pathway critical to the development of a wide variety of diseases, including acute lung injury, acute respiratory distress syndrome, bronchopulmonary dysplasia, systemic sepsis, acute liver and kidney injury, and pneumonia.  The company’s lead candidate, AZM-152, is a RHAMM-derived antagonist that blocks key upstream priming and activation signals involved in the aberrant activation of the NLRP3 inflammatory cascade.